Coherus BioSciences (CHRS) Reports Q3 Loss of $1.79
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.23 +1.65%
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
FWDI, GO, BATL, More
Financial Fact:
Selling, general, and administrative expenses: 137.78M
Today's EPS Names:
FWDI, GO, BATL, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.79), versus ($6.23) reported last year. Revenue for the quarter came in at $16.1 million, versus $500 thousand reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Okta upgraded as AI security opportunity boosts outlook
- Home Depot CEO takes medical leave 6 days before Q2 earnings
- BrainsWay Ltd. (BWAY) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
